{"title":"Concerns on methodological assumptions in the health economic evaluation of return-to-work interventions.","authors":"Afschin Gandjour","doi":"10.1080/14737167.2026.2629352","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>High sickness absence and disability claims create major societal and budget pressures, making return-to-work (RTW) interventions a central policy priority. Because decisions often hinge on whether productivity gains are counted, robust long-horizon economic models are influential - but also vulnerable to strong extrapolation assumptions.</p><p><strong>Areas covered: </strong>This Key Paper Evaluation examines a recent modeling study of RTWinterventions comparing a 3½-week inpatient multimodal occupational rehabilitation (I-MORE) with outpatient Acceptance and Commitment Therapy (ACT). The authors link a randomized trial to 7 years of registry follow-up and project costs and effects over a 25-year horizon from healthcare and societal perspectives.</p><p><strong>Expert commentary: </strong>The analysis is transparent and well executed, but the study's headline finding - lifetime dominance of I-MORE when productivity is counted - hinges on structural assumptions that effectively extend a 3½-week inpatient program into persistent productivity gains over a 25-year horizon: transition intensities are frozen beyond 4 years, and within-state absence-day differences are held constant thereafter, generating persistent productivity gains even after state prevalences converge. Health-related quality of life is observed only to 14 months and then modeled as state-specific constants, compressing incremental quality-adjusted life years and leaving the healthcare-only incremental cost-effectiveness ratio unfavorable. We argue that lifetime savings should be treated as upper-bound estimates and that decision relevance would be strengthened by waning-effect scenarios, mid-term horizons, and tests of the absorbing disability state. We also highlight the need for diagnosis-by-treatment analyses and stepped-care sequences given the heterogeneous population and fixed-dose ACT comparator.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"313-316"},"PeriodicalIF":2.2000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2026.2629352","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: High sickness absence and disability claims create major societal and budget pressures, making return-to-work (RTW) interventions a central policy priority. Because decisions often hinge on whether productivity gains are counted, robust long-horizon economic models are influential - but also vulnerable to strong extrapolation assumptions.
Areas covered: This Key Paper Evaluation examines a recent modeling study of RTWinterventions comparing a 3½-week inpatient multimodal occupational rehabilitation (I-MORE) with outpatient Acceptance and Commitment Therapy (ACT). The authors link a randomized trial to 7 years of registry follow-up and project costs and effects over a 25-year horizon from healthcare and societal perspectives.
Expert commentary: The analysis is transparent and well executed, but the study's headline finding - lifetime dominance of I-MORE when productivity is counted - hinges on structural assumptions that effectively extend a 3½-week inpatient program into persistent productivity gains over a 25-year horizon: transition intensities are frozen beyond 4 years, and within-state absence-day differences are held constant thereafter, generating persistent productivity gains even after state prevalences converge. Health-related quality of life is observed only to 14 months and then modeled as state-specific constants, compressing incremental quality-adjusted life years and leaving the healthcare-only incremental cost-effectiveness ratio unfavorable. We argue that lifetime savings should be treated as upper-bound estimates and that decision relevance would be strengthened by waning-effect scenarios, mid-term horizons, and tests of the absorbing disability state. We also highlight the need for diagnosis-by-treatment analyses and stepped-care sequences given the heterogeneous population and fixed-dose ACT comparator.
期刊介绍:
Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review.
The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.